Michael Kammer

Michael Kammer

Auto-generated profile, based on publicly available information

Michael Kammer

Institute of Clinical Biometrics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Lancet
Verified
Journal Article
Closed access
RRRoman Reindl-Schwaighofer
Roman Reindl-Schwaighofer
AHAndreas Heinzel
Andreas Heinzel
AKAlexander Kainz
Alexander Kainz
JSJessica van Setten
Jessica van Setten
KJKira Jelencsics
Kira Jelencsics
RORainer Oberbauer
Rainer Oberbauer

1 December 2016 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PKPaul A. Kyrle
Paul A. Kyrle
MKM. Kammer
M. Kammer
LEL. Eischer
L. Eischer
AWA. Weltermann
A. Weltermann
EME. Minar
E. Minar
SES. Eichinger
S. Eichinger

1 July 2014 in Journal of Computing in Civil Engineering
Verified
Journal Article
Closed access
PNPhilippe Nitsche
Philippe Nitsche
RSRainer Stütz
Rainer Stütz
MKMichael Kammer
Michael Kammer
PMPeter Maurer
Peter Maurer

1 April 2018 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MHMaria C Haller
Maria C Haller
MKMichael Kammer
Michael Kammer
RORainer Oberbauer
Rainer Oberbauer
Pre-emptive kidney transplantation is the recommended strategy for patients with end-stage renal failure in all guidelines [Kidney Disease: Improving Global Outcomes (KDIGO), The Australian and New Zealand Dialysis and Transplantation Registry (ANZDATA), European Renal Best Practice Guideline (ERBP), British Transplant Society (BTS)]. This recommendation is intuitive and based on few older studies with considerable limitations. In addition, there is conflicting evidence as to whether the duration of dialysis vintage impacts on graft and patient survival after transplantation. The objective of this structured review was to critically review the published evidence on dialysis vintage and outcomes by including the most recent papers on that topic. We searched Medline using keywords for kidney transplantation, pre-emptive, dialysis vintage and relevant outcomes, and found 14 eligible cohort studies. The best evidence was found for pre-emptive transplantation, which was found to be associated with a lower risk of actual graft loss (including death as event) compared with non-pre-emptive transplantation. When only patients were considered that have been registered pre-emptively but then received or did not receive a pre-emptive transplant, the association with functional graft survival (excluding death as event) was only marginal. Dialysis vintage had a graded association with patient survival in most of the studies, but an unclear estimate with functional graft survival. Older studies also found an association of dialysis vintage with death-censored graft survival, but this association is likely confounded by selection and the competing risk of death and was no longer observed in recent eras, i.e. in transplants performed in the last decade. In summary, the recommendation for pre-emptive kidney transplantation for optimal patient and graft survival remains valid even in recent periods but the association of dialysis vintage after dialysis initiation with death-censored graft survival is less clear. The association of dialysis vintage with mortality after transplantation depends on the median duration of dialysis of the wait-listed population as well as acceptance rates for transplantation, and may thus be country specific. Nevertheless, it is reasonable to advocate pre-emptive kidney transplantation in all age groups. What remains unsolved is the selection issues since the reasons for longer waiting time on dialysis are difficult to capture in retrospective observational studies, and lead time as well as immortal time bias may have confounded the mortality data.

1 December 2019 in Kidney International
Verified
Journal Article
Closed access
MKMichael Kammer
Michael Kammer
AHAndreas Heinzel
Andreas Heinzel
JWJill A. Willency
Jill A. Willency
KDKevin L. Duffin
Kevin L. Duffin
GMGert Mayer
Gert Mayer
RORainer Oberbauer
Rainer Oberbauer

6 July 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
AHAndreas Heinzel
Andreas Heinzel
MKMichael Kammer
Michael Kammer
GMGert Mayer
Gert Mayer
RRRoman Reindl-Schwaighofer
Roman Reindl-Schwaighofer
KHKarin Hu
Karin Hu
RORainer Oberbauer
Rainer Oberbauer
OBJECTIVE The decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes is variable, and early interventions would likely be cost-effective. We elucidated the contribution of 17 plasma biomarkers to the prediction of eGFR loss on top of clinical risk factors. RESEARCH DESIGN AND METHODS We studied participants in PROVALID (PROspective cohort study in patients with type 2 diabetes mellitus for VALIDation of biomarkers), a prospective multinational cohort study of patients with type 2 diabetes and a follow-up of more than 24 months (n = 2,560; baseline median eGFR, 84 mL/min/1.73 m2; urine albumin-to-creatinine ratio, 8.1 mg/g). The 17 biomarkers were measured at baseline in 481 samples using Luminex and ELISA. The prediction of eGFR decline was evaluated by linear mixed modeling. RESULTS In univariable analyses, 9 of the 17 markers showed significant differences in median concentration between stable and fast-progressing patients. A linear mixed model for eGFR obtained by variable selection exhibited an adjusted R2 of 62%. A panel of 12 biomarkers was selected by the procedure and accounted for 34% of the total explained variability, of which 32% was due to 5 markers. The individual contribution of each biomarker to the prediction of eGFR decline on top of clinical predictors was generally low. When included into the model, baseline eGFR exhibited the largest explained variability of eGFR decline (R2 of 79%), and the contribution of each biomarker dropped below 1%. CONCLUSIONS In this longitudinal study of patients with type 2 diabetes and maintained eGFR at baseline, 12 of the 17 candidate biomarkers were associated with eGFR decline, but their predictive power was low.